Source/Disclosures
Published by:
Source:
Boyer D. Opthea as an add on to anti-VEGF therapy. Presented at: Retina World Congress; May 12-15, 2022; Fort Lauderdale, Fla.
Disclosures:
Boyer reports being an investigator and scientific adviser to Opthea.
Read next
May 14, 2022
1 min watch
Save
VIDEO: OPT-302 enrolling for two phase 3 clinical trials
Source/Disclosures
Published by:
Source:
Boyer D. Opthea as an add on to anti-VEGF therapy. Presented at: Retina World Congress; May 12-15, 2022; Fort Lauderdale, Fla.
Disclosures:
Boyer reports being an investigator and scientific adviser to Opthea.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, David S. Boyer, MD, discusses the progress of two phase 3 clinical trials for OPT-302 in combination with either ranibizumab or aflibercept.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
